Clinical Trials
8 trialsNCT05773274 2026-05-26
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06900595 2026-05-22
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06959641 2026-05-22
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Northwestern University
Phase 2 Recruiting
NCT04665739 2026-05-13
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT06006013 2026-02-18
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
Phase 2 Recruiting
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT06788886 2025-12-30
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
Mayo Clinic
Phase NA Recruiting